Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer

Abstract

The degree of damage to DNA following ifosfamide (IFO) treatment may be linked to the therapeutic efficacy. The pharmacokinetics and metabolism of IFO were studied in 19 paediatric patients, mostly with rhabdomyosarcoma or Ewings sarcoma. Ifosfamide was dosed either as a continuous infusion or as fractionated doses over 2 or 3 days. Samples of peripheral blood lymphocytes were obtained during and up to 96 h after treatment, and again prior to the next cycle of chemotherapy. DNA damage was measured using the alkaline COMET assay, and quantified as the percentage of highly damaged cells per sample. Samples were also taken for the determination of IFO and metabolites. Pharmacokinetics and metabolism of IFO were comparable with previous studies. Elevations in DNA damage could be determined in all patients after IFO administration. The degree of damage increased to a peak at 72 h, but had returned to pretreatment values prior to the next dose of chemotherapy. There was a good correlation between area under the curve of IFO and the cumulative percentage of cells with DNA damage (r 2 ¼ 0.554, P ¼ 0.004), but only in those patients receiving fractionated dosing. The latter patients had more DNA damage (mean7s.d., 27367597) than those patients in whom IFO was administered by continuous infusion (14537730). The COMET assay can be used to quantify DNA damage following IFO therapy. Fractionated dosing causes a greater degree of DNA damage, which may suggest a greater degree of efficacy, with a good correlation between pharmacokinetic and pharmacodynamic data.

Differential Genetic and Functional Markers of Second Neoplasias in Hodgkin's Disease Patients

“…On this, data in the literature are inconclusive. Whereas some authors observed that induced damage with chemotherapy or radiotherapy returned to pretreatment values in a short term (27,28), other reports show the persistence of the injury in the lymphocytes (28,29). Very few publications show long followup periods.…”

Predicting Metabolism‐Related Drug–Drug Interactions Using a Microphysiological Multitissue System

“…Based on previous experiments we used CP and IFF concentrations of 1 × 10 −3 m. [ 33 ] Maximum blood plasma concentrations in patients, depending on the administration route and dosing regimen, were reported to range between 80 × 10 −6 and 157 × 10 −6 m for CP [ 50–52 ] and between 75 × 10 −6 and 350 × 10 −6 m for IFF. [ 53–55 ] RTV successfully inhibited CYP3A4 at concentrations of 1 × 10 −6 m , while reported blood plasma concentrations in HIV patients were between 10 × 10 −6 and 22 × 10 −6 m. [ 56 ] Compared to the in vivo situation, our testing system required tenfold higher prodrug concentrations but a comparably low RTV concentration to obtain full CYP3A4 inhibition. These observations can be explained by the lower metabolic capacity of the in vitro system in comparison to the in vivo situation.…”

New role for nuclear hormone receptors and coactivators in regulation of BRCA1-mediated DNA repair in breast cancer cell lines

“…DNA damage was quantified by single-cell gel electrophoresis [ 27 , 28 ]. Drug-treated cells were mixed with 0.5% low-melting-point agarose and added to microscope slides coated with 1.5% agarose.…”